Did the company disclose any changes in its capital structure, such as equity offerings, debt financing, or share buybacks?

Capital‑structure disclosure: The Q2 2025 release from ArriVent BioPharma does not contain any language about new equity offerings, debt issuances, refinancing, or share‑repurchase activity. The press‑release is limited to operating results and recent scientific progress, with no mention of a capital‑raising transaction or a buy‑back program.

Trading implications: Because the company has not announced any financing or buy‑back activity, the market should not price in dilution or cash‑flow effects that often accompany equity or debt issuances. In the absence of a new capital infusion, the company’s balance‑sheet will remain largely unchanged from the prior quarter, so any valuation impact will stem primarily from its operating performance and pipeline milestones. Traders should therefore focus on the core fundamentals—cash burn, runway, and upcoming data readouts—rather than expecting a short‑term price move from capital‑structure changes. Technically, the stock’s recent price action will be driven more by the Q2 earnings surprise (if any), forward guidance, and overall biotech sector sentiment; watch for volume spikes around the earnings release and any subsequent analyst commentary for the next actionable signal.